Dr. Rajeev C. Mohan, MD
Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)
9898 Genesee Ave
La Jolla, CA 92037
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Drexel University College of Medicine (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 2,275
Licensed in California since 2012, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: Drexel University College of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Advanced Heart Failure and Transplant Cardiology Physician primary
CA license A120615 (first issued 2012; current) -
Cardiovascular Disease Physician
CA license A120615 (first issued 2012; current) -
Internal Medicine Physician
PA license MT192782
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Heart Failure & Transplant Cardiology per capita by county →
Where they work
Hospitals
- Scripps Memorial Hospital La Jolla La Jolla, CA
- Scripps Mercy Hospital San Diego, CA
- Scripps Green Hospital La Jolla, CA
Medical groups
- Scripps Health (1,433 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 2,275
- Services billed
- 4,815
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 869 | 842 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 589 | 584 |
| Heart muscle strain imaging | 316 | 313 |
| Established patient office or other outpatient visit, 30-39 minutes | 254 | 168 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 215 | 84 |
| Injection, regadenoson, 0.1 mg | 205 | 52 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 158 | 155 |
| Injection, perflutren lipid microspheres, per ml | 130 | 65 |
| Critical care, first 30-74 minutes | 109 | 37 |
| Established patient office or other outpatient visit, 40-54 minutes | 95 | 75 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Vyndamax (tafamidis) | 136 |
| Spironolactone Other prescribers in La Jolla, CA | 87 |
| Metoprolol Succinate Other prescribers in La Jolla, CA | 67 |
| Jardiance (empagliflozin) Other prescribers in La Jolla, CA | 60 |
| Farxiga (dapagliflozin propanediol) Other prescribers in La Jolla, CA | 57 |
| Entresto (sacubitril/valsartan) Other prescribers in La Jolla, CA | 53 |
| Furosemide Other prescribers in La Jolla, CA | 49 |
| Eliquis (apixaban) Other prescribers in La Jolla, CA | 41 |
| Atorvastatin Calcium Other prescribers in La Jolla, CA | 40 |
| Carvedilol Other prescribers in La Jolla, CA | 33 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 23 companies reported 121 payments worth $112,409 in total to this clinician.
| Bridgebio Pharma, Inc. | $31,446 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $20,889 |
| Pfizer Inc. | $18,893 |
| Cvrx, Inc. | $15,566 |
| Alnylam Pharmaceuticals Inc. | $10,391 |
| AstraZeneca Pharmaceuticals LP | $6,817 |
| Bayer HealthCare Pharmaceuticals Inc. | $6,095 |
| Boston Scientific Corporation | $1,401 |
| Compensation for services other than consulting (speaking, faculty) | $66,075 |
|---|---|
| Consulting Fee | $37,347 |
| Travel and Lodging | $5,587 |
| Food and Beverage | $3,401 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. May 3, 2025 | Consulting Fee Kerendia · Cardio-Renal | $5,728 |
| Pfizer Inc. Aug 28, 2025 | Consulting Fee VYNDAMAX · CARDIOVASCULAR | $5,500 |
| E.r. Squibb & Sons, L.l.c. Jul 25, 2025 | Compensation for services other than consulting (speaking, faculty) CAMZYOS · Cardiovascular | $5,370 |
| E.r. Squibb & Sons, L.l.c. Apr 2, 2025 | Compensation for services other than consulting (speaking, faculty) CAMZYOS · Cardiovascular | $4,475 |
| E.r. Squibb & Sons, L.l.c. Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) CAMZYOS · Cardiovascular | $4,475 |
| Pfizer Inc. Nov 20, 2025 | Consulting Fee VYNDAQEL · CARDIOVASCULAR | $4,400 |
| Cvrx, Inc. Apr 8, 2025 | Consulting Fee Barostim Neo System · Heart Failure and Hypertension | $4,394 |
| Bridgebio Pharma, Inc. Dec 24, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $4,190 |
| Pfizer Inc. May 16, 2025 | Consulting Fee VYNDAQEL · CARDIOVASCULAR | $4,125 |
| Cvrx, Inc. Mar 4, 2025 | Consulting Fee Barostim Neo System · Heart Failure and Hypertension | $3,800 |
All 49 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Bridgebio Pharma, Inc. Dec 24, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $4,190 |
| Bridgebio Pharma, Inc. Dec 24, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,793 |
| Bridgebio Pharma, Inc. Dec 24, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $1,862 |
| Bridgebio Pharma, Inc. Dec 18, 2025 | Travel and Lodging Attruby · Cardiomyopathy · travel to San Jose, CA | $175 |
| Bridgebio Pharma, Inc. Dec 9, 2025 | Travel and Lodging Attruby · Cardiomyopathy · travel to San Jose, CA · in-kind | $567 |
| Bridgebio Pharma, Inc. Dec 9, 2025 | Travel and Lodging Attruby · Cardiomyopathy · travel to San Jose, CA · in-kind | $345 |
| Bridgebio Pharma, Inc. Dec 5, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,793 |
| Bridgebio Pharma, Inc. Dec 5, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,793 |
| Cvrx, Inc. Dec 4, 2025 | Consulting Fee Barostim Neo System · Heart Failure and Hypertension | $1,000 |
| Alnylam Pharmaceuticals Inc. Dec 2, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $3,150 |
| Pfizer Inc. Nov 26, 2025 | Compensation for services other than consulting (speaking, faculty) VYNDAQEL · CARDIOVASCULAR | $547 |
| Pfizer Inc. Nov 20, 2025 | Consulting Fee VYNDAQEL · CARDIOVASCULAR | $4,400 |
| Pfizer Inc. Nov 19, 2025 | Compensation for services other than consulting (speaking, faculty) VYNDAQEL · CARDIOVASCULAR | $3,125 |
| Pfizer Inc. Nov 14, 2025 | Consulting Fee VYNDAQEL · CARDIOVASCULAR | $1,100 |
| Bridgebio Pharma, Inc. Nov 12, 2025 | Travel and Lodging Attruby · Cardiomyopathy · travel to Loma Linda, CA · in-kind | $1,193 |
| Cvrx, Inc. Oct 22, 2025 | Consulting Fee Barostim Neo System · Heart Failure and Hypertension | $2,000 |
| Bridgebio Pharma, Inc. Oct 20, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,793 |
| Bridgebio Pharma, Inc. Oct 20, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $1,397 |
| E.r. Squibb & Sons, L.l.c. Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) CAMZYOS · Cardiovascular | $4,475 |
| Cvrx, Inc. Oct 9, 2025 | Consulting Fee Barostim Neo System · Heart Failure and Hypertension | $1,000 |
| Alnylam Pharmaceuticals Inc. Oct 1, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $3,150 |
| E.r. Squibb & Sons, L.l.c. Sep 23, 2025 | Travel and Lodging CAMZYOS · Cardiovascular · travel to Tustin, CA | $697 |
| Cvrx, Inc. Sep 10, 2025 | Consulting Fee Barostim Neo System · Heart Failure and Hypertension | $200 |
| Pfizer Inc. Aug 28, 2025 | Consulting Fee VYNDAMAX · CARDIOVASCULAR | $5,500 |
| AstraZeneca Pharmaceuticals LP Aug 13, 2025 | Compensation for services other than consulting (speaking, faculty) WAINUA · Cardiovascular and Metabolism Company’s descriptionSpeaker Fee | $2,150 |
| Bridgebio Pharma, Inc. Aug 7, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,793 |
| Bridgebio Pharma, Inc. Aug 7, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,793 |
| Bridgebio Pharma, Inc. Jul 28, 2025 | Travel and Lodging Attruby · Cardiomyopathy · travel to Long Beach, CA · in-kind | $808 |
| E.r. Squibb & Sons, L.l.c. Jul 25, 2025 | Compensation for services other than consulting (speaking, faculty) CAMZYOS · Cardiovascular | $5,370 |
| E.r. Squibb & Sons, L.l.c. Jul 10, 2025 | Travel and Lodging CAMZYOS · Cardiovascular · travel to Palm Desert, CA | $1,085 |
| Bridgebio Pharma, Inc. Jul 3, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $1,862 |
| AstraZeneca Pharmaceuticals LP Jul 2, 2025 | Compensation for services other than consulting (speaking, faculty) WAINUA · Cardiovascular and Metabolism Company’s descriptionSpeaker Fee | $2,150 |
| Bridgebio Pharma, Inc. Jun 5, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $1,862 |
| Alnylam Pharmaceuticals Inc. Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $3,150 |
| Alnylam Pharmaceuticals Inc. Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $473 |
| Cvrx, Inc. May 20, 2025 | Consulting Fee Barostim Neo System · Heart Failure and Hypertension | $2,850 |
| Pfizer Inc. May 16, 2025 | Consulting Fee VYNDAQEL · CARDIOVASCULAR | $4,125 |
| Bayer HealthCare Pharmaceuticals Inc. May 3, 2025 | Consulting Fee Kerendia · Cardio-Renal | $5,728 |
| Bayer HealthCare Pharmaceuticals Inc. May 3, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to San Diego, CA · in-kind | $29.26 |
| Bayer HealthCare Pharmaceuticals Inc. May 2, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to San Diego, CA · in-kind | $20.00 |
| Boston Scientific Corporation May 1, 2025 | Consulting Fee General - Structural Heart · General - Structural Heart_IC | $1,250 |
| Cvrx, Inc. Apr 8, 2025 | Consulting Fee Barostim Neo System · Heart Failure and Hypertension | $4,394 |
| E.r. Squibb & Sons, L.l.c. Apr 2, 2025 | Compensation for services other than consulting (speaking, faculty) CAMZYOS · Cardiovascular | $4,475 |
| E.r. Squibb & Sons, L.l.c. Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) CAMZYOS · Cardiovascular | $3,580 |
| E.r. Squibb & Sons, L.l.c. Mar 12, 2025 | Travel and Lodging CAMZYOS · Cardiovascular · travel to Tustin, CA | $669 |
| Cvrx, Inc. Mar 4, 2025 | Consulting Fee Barostim Neo System · Heart Failure and Hypertension | $3,800 |
| AstraZeneca Pharmaceuticals LP Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) WAINUA · Cardiovascular and Metabolism Company’s descriptionSpeaker Fee | $2,150 |
| AstraZeneca Pharmaceuticals LP Jan 23, 2025 | Compensation for services other than consulting (speaking, faculty) WAINUA · Cardiovascular and Metabolism Company’s descriptionSpeaker Fee | $100 |
| AstraZeneca Pharmaceuticals LP Jan 23, 2025 | Compensation for services other than consulting (speaking, faculty) WAINUA · Cardiovascular and Metabolism Company’s descriptionSpeaker Fee | $100 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $20,149 in research payments for these studies, mostly to the institutions running them.
- LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.
Boston Scientific Corporation · Completed · NCT04790344 - Tracking treatment pathways in adult patients with hyperkalemia (TRACK)
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.